These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38582540)

  • 1. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
    Long Y; Wang H; Xie X; Li J; Xu Y; Zhou Y
    BMJ Open; 2024 Apr; 14(4):e077090. PubMed ID: 38582540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.
    Gan Y; Shi F; Zhu H; Han S; Li D
    Front Pharmacol; 2023; 14():1241130. PubMed ID: 37547339
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
    Long Y; Xu Y; Liao L; Zhou Y; Wang H
    BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L; Zhou Z; Zeng X; Tan C; Liu Q
    Front Immunol; 2024; 15():1408928. PubMed ID: 39035009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.
    You M; Chen R; Wu Q; Zhu W; He Y; Huang Y
    Front Pharmacol; 2022; 13():1019826. PubMed ID: 36386191
    [No Abstract]   [Full Text] [Related]  

  • 7. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
    Liu G; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Qin Q; Zhu H
    Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China.
    Zhou D; Dong X; Zhou Z; Liu Q
    Risk Manag Healthc Policy; 2023; 16():2521-2529. PubMed ID: 38024490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
    Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
    Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
    Chen F; Long Y; Yang J; Zhong K; Liu B
    BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
    Li LY; Wang H; Chen X; Li WQ; Cui JW
    Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
    Meng M; Liu X; Liang X; Chen X; Li Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.